Scientific Presentations

Autoimmune Diseases

“Safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742, a RORgt antagonist, in healthy volunteers”
Presented at IMMUNOLOGY 2016: The American Association of Immunologists’ Annual Meeting, May 13-17, 2016
Download PDF

“The RORγt Blocker, VTP-43742, Suppresses Th17 Activity Providing Greater Benefit than IL-17A Blockade in an EAE Model of Autoimmunity”
Presented at the Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases, April 23, 2015
Download PDF

“The potent, selective RORgt blocker, VTP-43742, suppresses Th17 production in vivo
and provides greater benefit than IL-17A blockade in the EAE model of autoimmunity”
Presented at IMMUNOLOGY 2015: The American Association of Immunologists Annual Meeting, May 9, 2015
Download PDF

“VTP-43742 is a Potent and Selective RORγt Blocker That Demonstrates Oral Efficacy in a Mouse Model of Autoimmunity Through Suppression of IL-17A Production”
Presented at IMMUNOLOGY 2015: The American Association of Immunologists Annual Meeting, May 10, 2015
Download PDF

Atopic Dermatitis

“The LXR Ligand VTP-38543 Represents a New Class of Therapeutic
Agents for the Treatment of Atopic Dermatitis”
Presented at the 2015 Society for Investigative Dermatology Annual Meeting, May 9, 2015

Download PDF

Acute Coronary Syndrome

“The LXRβ Selective Agonist, VTP-38443, Significantly Decreases Plaque Cholesterol
Ester Content and Inflammation in a Murine Model of Accelerated Atherosclerosis”
Presented at Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral Vascular Disease 2015 Scientific Sessions, May 8, 2015

Download PDF